NICE recommendation of darolutamide plus hormone therapy for metastatic prostate cancer offers around 6000 patients in ...
In hormone-sensitive prostate cancer, an alternative dosing of docetaxel plus Nubeqa and ADT was associated with improvements in side effect rates.
The Nubeqa (darolutamide) regimen can be used to treat adult patients with advanced HSPC if docetaxel, a chemotherapy agent, ...
Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.
Final draft guidance on NHS use of the drug marks a "significant shift" from NICE's 2021 decision on the drug as a first-line ...
Androgen receptor pathway inhibitors (ARPIs) in combination with androgen deprivation therapy (ADT) represent the foundation ...
The UK’s National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending the use of ...
Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.
Combinations of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) are the accepted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback